Navigation Links
New Protein Inhibitor Halts Growth Of Cancerous Cells

Researchers reporting their findings in the current Biology online on February 8, have developed a small-molecule inhibitor of a protein that plays// key roles in the control of cell division. The researchers show that the inhibitor can halt the growth of tumors in mice and cancer-derived cells growing in culture.

The findings are reported in companion papers reported by two collaborating groups—one (Lenart et al.) led by Jan-Michael Peters of the Research Institute of Molecular Pathology in Vienna, and the other (Steegmaier et al.) led by Norbert Kraut of Boehringer Ingelheim Austria GmbH.

Because cancer cells are typically fast growing and can mutate to adapt to new growth conditions, effective drug-based therapies will likely succeed in part by impeding multiple functions required for cell division and survival. One particular class of proteins, known as kinases, is known to play especially critical roles in the division of healthy cells, and appears to also be important for cell division in cancer cells, even though these cells are diseased and have lost some of the restraints on division that normal cells impose on themselves.

Because central aspects of cell division are under the control of just a few key kinases, these proteins represent potentially important targets for new cancer therapeutics, but few if any effective inhibitors have been identified as acting specifically and effectively against one particular cell-division kinase, known as Plk1.

In the new work, Steegmaier et al. isolated a chemical compound, which they term BI 2536, that they demonstrate to be a potent inhibitor of Plk1, and show that BI 2536 can indeed effectively halt the growth of cancerous cells, both in cell culture and in an animal model for human tumor growth. BI 2536 caused growth arrest and cell death in cell lines derived from a variety of human cancers, and it inhibited the growth of human tumor grafts in mice, resulting in the death of tumor cells and regression of large tumors.

The authors report that BI 2536 has now been brought into use in clinical studies of patients with locally advanced or metastatic cancers in order to address the therapeutic potential of the compound.

In the companion paper, Lenart et al. use BI 2536 as a tool to probe the functions of Plk1 in normal cells. The availability of a specific Plk1 inhibitor is particularly useful in this regard because Plk1 is needed for a variety of different cellular processes required for cell division, and a chemical inhibitor such as BI 2536 allows Plk1 function to be experimentally disrupted at specific points during the cell-division cycle, thereby revealing the normal roles of Plk1 in new detail, and potentially identifying specific cellular processes that might be targeted by future anti-cancer therapeutics.

Source-Eurekalert
SRI
'"/>




Related medicine news :

1. Lean Protein Could Be Key to Obesity Drugs
2. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
3. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of ‘Huntingtons’ Disase
4. Unravelling the secrets of ‘Huntingtin’ Protein - towards the treatment of Huntingtins’ Disese
5. Protein in urine foresees heart disease
6. Levels Of Blood Proteins May Help Heart Disease Care
7. Protein signals need for heart surgery
8. Protein and fat improve memory
9. Clotting Protein plays a role in nerve repair
10. High Levels of Protein Linked to Brain Shrinkage
11. Protein can change worn muscle fibres
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... , ... June 26, 2016 , ... Brent Kasmer, a legally blind and certified personal ... personalized through a fitness app. The fitness app plans to fix the two major problems ... offer a one size fits all type program , They don’t eliminate all ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... -- Research and Markets has announced the ... (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), Functionality (Filler, ... Global Forecast to 2021" report to their offering. ... pharmaceutical excipients market is projected to reach USD 8.1 ... the forecast period 2016 to 2021. ...
(Date:6/23/2016)... , June 23, 2016 Research ... MEMS Devices Medical Market Analysis 2016 - Forecast to 2022" ... The report contains up to date financial data ... analysis. Assessment of major trends with potential impact on the ... analysis of market segmentation which comprises of sub markets, regional ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: